News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kaken Pharmaceuticals and ChemDiv, Inc. Partner in Drug Discovery Deal



2/26/2007 12:21:25 PM

SAN DIEGO, Feb. 26 /PRNewswire/ -- ChemDiv, Inc. of San Diego, CA, USA, and Kaken Pharmaceutical Co., Ltd. of Tokyo, Japan have announced today that they entered into a joint Drug Discovery collaboration involving undisclosed therapeutic targets.

ChemDiv is to produce lead candidates employing its Discovery outSource(TM) platform, including proprietary rational design, extensive medicinal chemistry and pre-clinical biology capabilities.

The designed chemical libraries will be screened at ChemDiv on Kaken's drug targets with a subsequent lead optimization effort.

Dr. Motoyuki Yajima, Executive Managing Director of Research and Development of Kaken commented: "We are delighted to be able to work with ChemDiv, as this collaboration combines the complementary skills of both companies to create new compounds to our innovative targets. We are very optimistic and happy to have found such a capable partner in ChemDiv."

Dr. Ilya Okun, VP Biology and CTO of ChemDiv, Inc. said: "We established and partnered a turnkey lead discovery platform based on ChemDiv's pre-clinical development services. That includes assay development and validation, screening and lead candidate characterization in secondary assays, animal efficacy models, PK and Tox. We are proud to further expand our successful collaboration with Kaken."

About Kaken:

Kaken Pharmaceutical Co., Ltd. (www.kaken.co.jp) traces back to the Institute of Physical & Chemical Research (Riken), which was established in 1917. The company entered the pharmaceutical business with penicillin and streptomycin, which were manufactured using Riken's technology in 1948. Kaken has since broadened its scope of activities through merger and alliance and has a presence in internal medicine, orthopedics and dermatology. Kaken has advanced its market presence by providing new drugs discovered with its own technology and through partnership and in-licensing. Kaken's commitment to "bringing smile to everyone" entails providing superior pharmaceuticals that improve patients' quality of life.

About ChemDiv, Inc.

ChemDiv (www.chemdiv.com) is a global chemistry-driven contract research organization focused on delivery of scientific innovation, identifying and delivering pre-clinical opportunities and services for life science partners, and merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. For over 16 years ChemDiv has provided Discovery outSource(TM) solutions, including medicinal and synthetic chemistry, pre-clinical development, screening libraries and global logistics. The ChemDiv international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.

Kaken Pharmaceutical Co., Ltd.; ChemDiv, Inc.

CONTACT: Ron Demuth, General Manager of ChemDiv, Inc., +1-858-794-4860, orfax, +1-858-794-4931


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES